Halozyme Therapeutics: Steady Growth In A Challenged Market
Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...
Zacks Investment Research on MSN2d
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...
MedPage Today on MSN3d
Once-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly Dosing
A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
JD Supra3d
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...
Coeur d'Alene Press3d
Coeur d'Alene support group hosting upcoming events for patients, families, caregivers
On and off. In the world of Parkinson's disease, "on" is often used to communicate that medication is working and symptoms ...
Targeted Oncology5d
Exploring Targeted Treatments and Their AEs in EGFR-Mutated NSCLC
During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.
Fierce Pharma5d
Viking pays $150M to recruit CordenPharma for obesity drug manufacturing saga
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
The American Journal of Managed Care6d
With Sub-Q Immunotherapy Coming, “Patient Preference Has to Be the Key”
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.